AhmadAwadaMD

Obstetrics & Gynecology • Orlando, FL

Gynecologic Oncology

Gynecology Oncology Fellow

Join to view full profile

Dr. Awada is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Awada's full profile

Already have an account?

Office
601 east Rollins street
Orlando, FL 32814
Is this information wrong?

Education & Training

George Washington UniversityResidency, Obstetrics and Gynecology, 2010 - 2014
American University of Beirut Faculty of MedicineClass of 2009

Certifications & Licensure

MI State Medical License 2024 - 2027
FL State Medical License 2021 - 2025
NY State Medical License 2018 - 2021
PA State Medical License 2014 - 2021
VA State Medical License 2010 - 2014
DC State Medical License 2010 - 2012
American Board of Obstetrics and Gynecology Obstetrics & Gynecology

Clinical Trials

EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients Start of enrollment: 2007 Jan 01
Completed
Phase 2
Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx Start of enrollment: 2007 May 01
Completed
Phase 1, Phase 2
A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour Start of enrollment: 2008 Oct 01
Completed
Phase 1
A Study of ARGX-110 in Participants With Advanced Malignancies Start of enrollment: 2013 Feb 27
Completed
Phase 1, Phase 2
A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors Start of enrollment: 2017 Sep 19
Active, not recruiting
Phase 1, Phase 2
A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma Start of enrollment: 2018 Jan 18
Terminated
Phase 1, Phase 2
Futibatinib in Patients With Specific FGFR Aberrations Start of enrollment: 2020 Aug 24
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Forchlorfenuron-Induced Mitochondrial Respiration Inhibition and Metabolic Shifts in Endometrial Cancer.
Kyukwang Kim, Negar Khazan, Rachael B Rowswell-Turner, Rakesh K Singh, Taylor Moore, Myla S Strawderman, John P Miller, Cameron W A Snyder, Ahmad Awada, Richard G Moore> ;Cancers. 2024 Feb 28
Prognostic features of the tumor microenvironment in high-grade serous ovarian cancer and dietary immunomodulation.
Nathalie D McKenzie, Sarfraz Ahmad, Ahmad Awada, Theresa M Kuhn, Fernando O Recio, Robert W Holloway> ;Life Sciences. 2023 Nov 15
Malignant peritoneal cytologic contamination with robotic hysterectomy for endometrial cancer.
Nnamdi I Gwacham, Karolina A Kilowski, Fernando O Recio, Ahmad Awada, Theresa M Kuhn, Jianbin Zhu, Ameya Patel, Sarfraz Ahmad, Nathalie D McKenzie, James E Kendrick, R...> ;Gynecologic Oncology. 2023 Aug 1
5 citations
Immunotherapy in the Treatment of Platinum-Resistant Ovarian Cancer: Current Perspectives.
Ahmad Awada, Sarfraz Ahmad, Nathalie D McKenzie, Robert W Holloway> ;Oncotargets and Therapy. 2022 Jan 1
12 citations
Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomiz...
Véronique Diéras, Hervé Bonnefoi, Emilio Alba, Ahmad Awada, Bruno Coudert, Xavier Pivot, Joseph Gligorov, Agnes Jager, Stefania Zambelli, Geoffrey J. Lindeman, Eric Ch...> ;Breast Cancer Research and Treatment. 2019 Jun 6
6 citations
Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate.
Nuria Kotecki, Andrea Gombos, Ahmad Awada> ;Expert Review of Anticancer Therapy. 2019 May 13
9 citations
Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task F...
Christel Fontaine, V. Renard, Heidi Van den Bulk, Peter Vuylsteke, Philip Glorieux, Catherine Dopchie, Lore Decoster, Leen Vanacker, Evandro de Azambuja, Jacques De Gr...> ;Breast Cancer Research and Treatment. 2019 May 8
2 citations
Promising Immuno-Oncology Treatments Beyond the 2018 Nobel Prize.
Luís Castelo-Branco, Ines Pires da Silva, Helena Canhão, Ahmad Awada> ;Acta Medica Portuguesa. 2019 Apr 30
12 citations
Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer
Georges El Hachem, Andrea Gombos, Ahmad Awada> ;F1000research. 2019 Apr 30
488 citations
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.
Sylvia Adams, Peter Schmid, Hope S. Rugo, Eric P. Winer, Delphine Loirat, Ahmad Awada, David W. Cescon, Hiroji Iwata, Mario Campone, Rita Nanda, Rina Hui, Giuseppe Cur...> ;Annals of Oncology. 2019 Mar 1
300 citations
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.
Stephen R. D. Johnston, Miguel Martin, Angelo Di Leo, Seock-Ah Im, Ahmad Awada, T. Forrester, Martin Frenzel, Molly C. Hardebeck, Joanne Cox, Susana Barriga, Masakazu ...> ;NPJ Breast Cancer. 2019 Jan 17
3 citations
Precision oncology: as much expectations as limitations
Vitor Fiorin de Vasconcellos, Leandro M. Colli, Ahmad Awada, Gilberto de Castro Junior> ;Ecancermedicalscience. 2018 Nov 29
24 citations
Risk factors for the development of brain metastases in patients with HER2-positive breast cancer.
Christian Maurer, Lorraine Tulpin, Michel Moreau, Cristina Dumitrescu, Evandro de Azambuja, Marianne Paesmans, Jean-Marie Nogaret, Martine Piccart, Ahmad Awada> ;ESMO Open. 2018 Jan 1
2 citations
Small cell carcinoma of the endometrium: A clinicopathological study and management of three cases.
Fatoumata Matokoma Sidibe, Zakaria Traore, Aspasia Georgala, Rajae Kanab, Denis Larsimont, Ahmad Awada, Martine Piccart-Gebhart> ;Bulletin Du Cancer. 2018 Sep 1
17 citations
Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma.
Mohammad Krayem, Ahmad Najem, Fabrice Journe, Renato Morandini, François Sales, Ahmad Awada, Ghanem Elias Ghanem> ;Oncotarget. 2018 Aug 7
28 citations
Therapy of breast cancer brain metastases: challenges, emerging treatments and perspectives:
Nuria Kotecki, Florence Lefranc, Daniel Devriendt, Ahmad Awada> ;Therapeutic Advances in Medical Oncology. 2018 Jun 22
24 citations
Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer
G. Basaran, Chris Twelves, Véronique Diéras, Javier Cortes, Ahmad Awada> ;Cancer Treatment Reviews. 2018 Feb 1
74 citations
PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies.
Anne Perdrix, Ahmad Najem, Sven Saussez, Ahmad Awada, Fabrice Journe, Ghanem Elias Ghanem, Mohammad Krayem> ;Cancers. 2017 Dec 16
368 citations
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised...
José Baselga, Seock–Ah –A Im, Hiroji Iwata, Javier Cortes, Michele De Laurentiis, Zefei Jiang, Carlos L. Arteaga, Walter Jonat, Mark Clemons, Yoshinori Ito, Ahmad Awad...> ;The Lancet. Oncology. 2017 Jul 1
63 citations
Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer
Marzia Locatelli, Philippe Aftimos, E. Claire Dees, Patricia LoRusso, Mark D. Pegram, Ahmad Awada, Bo Huang, Rossano Cesari, Yuqiu Jiang, Naveed Shaik, Kenneth A. Kern...> ;Oncotarget. 2017 Jan 1
4 citations
Advances in chemical pharmacotherapy to manage advanced breast cancer.
Andrea Gombos, Ahmad Awada> ;Expert Opinion on Pharmacotherapy. 2017 Jan 1
12 citations
Are virus-induced cancers more sensitive to checkpoint inhibitors?
Hassan Kanaan, Hampig Raphael Kourie, Ahmad Awada> ;Future Oncology. 2016 Aug 11
1 citations
Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation.
Linda Cairns, Sandrine Aspeslagh, Andrea A. Anichini, Jon Amund Kyte, Christian C. Blank, Paolo P. Ascierto, Nicolle N. Rekers, Per thor Straten, Ahmad Awada> ;Ecancermedicalscience. 2016 Nov 9
7 citations
Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors.
Sandrine Aspeslagh, Ahmad Awada, Arturo A.S. Matos-Pita, Philippe Aftimos, Rastilav Bahleda, Andrea Varga, Jean-Charles Soria> ;Anti-Cancer Drugs. 2016 Nov 1
28 citations
Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study
Sara M. Tolaney, Hovav Nechushtan, I. G. Ron, Patrick Schöffski, Ahmad Awada, Chris A. Yasenchak, A. Douglas Laird, Bridget O’Keeffe, Geoffrey I. Shapiro, Eric P. Winer> ;Breast Cancer Research and Treatment. 2016 Oct 6
Join now to see all

Lectures

Anti-tumor activity of PM1183 (lurbinectedin) in combination with capecitabine in metastatic breast cancer patients: Results from a phase I trial.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

PharmaMar Announces Data Presentations for Both Its Molecules Yondelis® and Lurbinectedin at ASCO 2018August 3rd, 2018
‘Fighting My Cancer as Much as Possible’: Why Many Patients Join Phase 1 Clinical TrialsMarch 8th, 2018
Neratinib plus Paclitaxel vs. Trastuzumab plus Paclitaxel in Breast CancerApril 14th, 2016